• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[3H]氟伐他汀在患有胆瘘的比格犬和恒河猴单次口服给药后的处置情况。

Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae.

作者信息

Tse F L, Dain J G, Kalafsky G

机构信息

Department of Drug Metabolism and Pharmacokinetics, Drug Safety, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

出版信息

Biopharm Drug Dispos. 1995 Apr;16(3):211-9. doi: 10.1002/bdd.2510160306.

DOI:10.1002/bdd.2510160306
PMID:7787133
Abstract

The disposition of [3H]fluvastatin was examined following single oral doses in dogs (12.4 mg kg-1) and monkeys (0.48 and 45.5 mg kg-1) with bile fistulae. Serial plasma and complete urine, feces, and bile were collected at designated intervals for 3 or 4 d, and were analyzed for total radioactivity and unchanged fluvastatin. In the dog, peak radioactivity concentrations (Cmax) averaged 7260 ng equiv. mL-1 and the mean time to peak (tmax) was approximately 9 h. In the monkey, the mean radioactivity tmax values were approximately 5 and 13 h following the low and high doses, the respective Cmax values being 116 and 10,400 ng equiv. mL-1. The mean AUC of total radioactivity was proportional to the dose while that of fluvastatin was overproportional to dose, suggesting dose independent absorption but saturable first-pass effect. The AUC ratio of unchanged fluvastatin versus total radioactivity was approximately 63% in the dog, and 9% and 13% for the low and high doses, respectively in the monkey. The bile was the major excretory route of radioactivity (dog, 56%; low-dose monkey, 73%; high-dose monkey, 69%) whereas the renal pathway accounted for < 5% of the dose in both species. Approximately 12% of the biliary radioactivity in the dog was due to intact fluvastatin, compared with 0% and 7.5% after the low and high doses in the monkey. These results showed a smaller extent of fluvastatin metabolism in the dog than in the monkey, and suggested that metabolism in the monkey was saturable in the dose range studied.

摘要

在患有胆瘘的犬(12.4 mg·kg⁻¹)和猴(0.48和45.5 mg·kg⁻¹)中,给予单次口服剂量后,研究了[³H]氟伐他汀的处置情况。在3或4天的指定时间间隔收集系列血浆以及完整的尿液、粪便和胆汁,并分析总放射性和未变化的氟伐他汀。在犬中,放射性浓度峰值(Cmax)平均为7260 ng等效物·mL⁻¹,达到峰值的平均时间(tmax)约为9小时。在猴中,低剂量和高剂量后放射性tmax的平均值分别约为5和13小时,各自的Cmax值分别为116和10400 ng等效物·mL⁻¹。总放射性的平均AUC与剂量成比例,而氟伐他汀的AUC与剂量超比例,表明吸收与剂量无关但首过效应饱和。在犬中,未变化的氟伐他汀与总放射性的AUC比值约为63%,在猴中,低剂量和高剂量分别为9%和13%。胆汁是放射性的主要排泄途径(犬为56%;低剂量猴为73%;高剂量猴为69%),而在两个物种中,肾脏途径占剂量的比例均小于5%。犬胆汁中约12%的放射性是由于完整的氟伐他汀,相比之下,猴在低剂量和高剂量后分别为0%和7.5%。这些结果表明,氟伐他汀在犬中的代谢程度低于猴,并且表明在研究的剂量范围内,猴中的代谢是饱和的。

相似文献

1
Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae.[3H]氟伐他汀在患有胆瘘的比格犬和恒河猴单次口服给药后的处置情况。
Biopharm Drug Dispos. 1995 Apr;16(3):211-9. doi: 10.1002/bdd.2510160306.
2
Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey.HMG -辅酶A还原酶抑制剂氟伐他汀在小鼠、大鼠、犬和猴体内的处置情况。
Biopharm Drug Dispos. 1990 Aug-Sep;11(6):519-31. doi: 10.1002/bdd.2510110606.
3
Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.氟伐他汀在正常志愿者单次及多次给药后的药代动力学。
J Clin Pharmacol. 1992 Jul;32(7):630-8. doi: 10.1002/j.1552-4604.1992.tb05773.x.
4
The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys.氟伐他汀(一种HMG-CoA还原酶抑制剂)在比格犬和恒河猴中的安全性评价。
Fundam Appl Toxicol. 1996 Jan;29(1):48-62. doi: 10.1006/faat.1996.0005.
5
Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.大鼠中氟伐他汀的肠道局部吸收及胆汁排泄:多药耐药相关蛋白2(MRP2)可能参与其中
Mol Pharm. 2004 Sep-Oct;1(5):347-56. doi: 10.1021/mp0499297.
6
Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit.HMG-CoA还原酶抑制剂氟伐他汀在兔体内的吸收与处置
Biopharm Drug Dispos. 1992 May;13(4):285-94. doi: 10.1002/bdd.2510130407.
7
Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients.氟伐他汀缓释片与环孢素在肾移植受者中的药代动力学相互作用评估。
Int J Clin Pharmacol Ther. 2006 Apr;44(4):163-71. doi: 10.5414/cpp44163.
8
Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC.
J Cardiovasc Pharmacol Ther. 2001 Apr;6(2):137-45. doi: 10.1177/107424840100600205.
9
Clinical pharmacokinetics of fluvastatin.氟伐他汀的临床药代动力学
Clin Pharmacokinet. 2001;40(4):263-81. doi: 10.2165/00003088-200140040-00003.
10
Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.酒精摄入对氟伐他汀药代动力学、疗效及安全性的影响。
Am J Cardiol. 1995 Jul 13;76(2):89A-96A. doi: 10.1016/s0002-9149(05)80026-8.

引用本文的文献

1
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.HMG-CoA还原酶抑制剂的药效学与药代动力学。异同点。
Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005.